Results 1 to 10 of about 21,458 (165)
BMJ, 2006 Last week an expert panel of the US Food and Drug Administration (FDA) recommended that the FDA should issue warnings to doctors and patients about drug eluting coronary stents. The safety of such stents is unclear except in low risk patients. Furthermore, patients with drug eluting stents should take antiplatelet therapy for at least one year after ...
Gershlick, AH, Richardson, G
+9 more sources
Canadian Medical Association Journal, 2007 In their recent systematic review, Suzanne Ligthart and associates compared analyses of the cost-effectiveness of drug-eluting stents.[1][1] They found that in most studies in which an incremental cost-effectiveness ratio greater than $50 000 per quality-adjusted life-year was calculated the ...
E Liana, Falcone, Navdeep, Tangri
openaire +4 more sources
CVIR Endovascular, 2021 Background Although several clinical reports demonstrated a durable patency rate after a novel fluoropolymer-coated paclitaxel-eluting stent (Eluvia; Boston Scientific, Marlborough, MA, USA) placement, aneurysmal degeneration after drug-eluting stent ...
Takuya Tsujimura +13 more
doaj +1 more source
Journal of the American Heart Association: Cardiovascular and Cerebrovascular Disease, 2021 Background Percutaneous coronary intervention of calcified lesions was associated with worse outcomes in the era of bare‐metal and first‐generation drug‐eluting stents. Data on percutaneous coronary intervention of calcified lesions with newer‐generation
Rayyan Hemetsberger +13 more
doaj +1 more source
Drug-eluting stent thrombosis [PDF]
Therapeutic Advances in Cardiovascular Disease, 2009 Stent thrombosis is a rare complication following stent implantation; if it occurs, however, it is associated with a high morbidity and mortality. Despite reduced rates of restenosis, drug-eluting stents (DES) have not reduced the incidence of stent thrombosis as compared with bare-metal stents (BMS).
Stähli, B E, Camici, G G, Tanner, F C
openaire +7 more sources
Stent thrombosis and drug-eluting stents [PDF]
Journal of Cardiology, 2011 Coronary stents have been used for the treatment of patients with coronary artery disease (CAD), and significantly improved procedural safety and are associated with a lower rate of restenosis compared with balloon angioplasty alone. Drug-eluting stents (DES) have been dominant for the treatment of CAD with efficacy in significantly reducing both ...
Takayama, Tadateru +2 more
openaire +2 more sources
The future of drug eluting stents [PDF]
Heart, 2005 In-stent restenosis (ISR) is the major drawback of percutaneous coronary interventions, occurring in 10–40% of patients. Drug eluting stents (DES) are successful in a large majority of patients in preventing restenosis for the first year after implantation.
Anis, RR, Karsch, KR
openaire +3 more sources
An Analysis of Cost-Effectiveness of Stents Used in the Treatment of Coronary Artery Disease
Balkan Medical Journal, 2019 Background: There is only limited information about the cost-effectiveness of drug-eluting stents compared with bare-metal stents in Turkey. Aims: To evaluate bare-metal and drug-eluting stents used in the treatment of coronary artery disease from the ...
Ferda Işıkçelik +2 more
doaj +1 more source
Case Reports in Medicine, 2009 Although safety profiles of sirolimus-eluting stents do not seem to differ in short-to-medium term from those of bare-metal stents, late stent thrombosis after deployment of drug-eluting stents has emerged as a potential safety concern in the era of high-
Dirk Sibbing +3 more
doaj +1 more source
The stenting strategy of drug-eluting stents for coronary artery disease in patients on dialysis
SAGE Open Medicine, 2014 Background: Reports regarding the relationship between the length and diameter of implanted drug-eluting stents and clinical and angiographic outcomes in dialysis patients are limited.
Hiroshi Fujita +6 more
doaj +1 more source